PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples
-
Published:2023-02-16
Issue:2
Volume:36
Page:177-191
-
ISSN:1875-8592
-
Container-title:Cancer Biomarkers
-
language:
-
Short-container-title:CBM
Author:
Möller Katharina1, Knöll Madeleine1, Bady Elena1, Schmerder Max Jonathan1, Rico Sebastian Dwertmann1, Kluth Martina1, Hube-Magg Claudia1, Blessin Niclas C.1, Mandelkow Tim1, Lennartz Maximilian1, Menz Anne1, Luebke Andreas M.1, Höflmayer Doris1, Fraune Christoph1, Bernreuther Christian1, Lebok Patrick1, Uhlig Ria1, Contreras Hendrina1, Weidemann Sören1, Gorbokon Natalia1, Jacobsen Frank1, Clauditz Till S.1, Steurer Stefan1, Burandt Eike1, Minner Sarah1, Sauter Guido1, Simon Ronald1, Marx Andreas H.12, Krech Till13
Affiliation:
1. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2. Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany 3. Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany
Abstract
BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes. RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin’s lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p< 0.0001 each). CONCLUSIONS: PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.
Subject
Cancer Research,Genetics,Oncology,General Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|